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Abstract
Background. To examine how often patients, with advanced disease and in need of improvement of pain
control, present with trigger points due to myofascial pain and nerve compression and if these trigger
points can be related to the pain spontaneously reported by patients.
Material and methods. Thirty three patients with advanced disease referred to different hospice services
for pain control participated in this study, which involved a pain history interview, palpation of areas prone
to development of trigger points and measurement of pressure pain thresholds (PPT) of these areas.
Results. On palpation, trigger points were found in 94% of the patients. In 67% of them trigger points
could be matched with the pains mentioned during the pain history interview. A significant correlation
was found between the low pressure pain thresholds of the control areas and those of the investigated
areas (r = 0.83, p < 0.01). An inverse relation was found between the number of trigger points and the
mean pressure pain threshold of the investigated areas (r = –0.63, p = 0.01).
Conclusion. Many patients with unrelieved pain in advanced disease may present with trigger points. The
origin can be peripheral. However, when multiple, a central cause such as spinal cord sensitisation should
be considered. Attention to trigger points and to their treatment has the potential for further improve-
ment of pain control.
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Introduction
Despite considerable developments in pain con-
trol in advanced disease, actual prevalence of pain
is not changing. This is true for cancer, and proba-
bly to an even greater extend for other chronic
diseases [1]. Several types of pain, usually less re-
sponsive to opioids, are still difficult to treat. Pa-
tients tend to complain of many pains at the same
time [2]. In a group of 111 cancer patients 370
pains were found with an average of 3 pains per
patient [3]. After treating the patients for 4 weeks
this number dropped to 1.5 pains per patient. Pains
unrelated to cancer still contributed considerably
to the overall pain. Several pains unrelated to can-
cer were identified and described in more detail
[4]. Myofascial but also nerve compression pain
can be related to cachexia, progressive debility and
lack of movement. Strain and muscle overuse can
also be causes. These types of pain are certainly not
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unique to cancer and may be encountered in nearly
all chronic and non-cancer diseases [5–8].
There is also a suggestion that malnutrition and
other co-morbidities may increase the vulnerability
of the nerve to damage [9–11]. Muscle weakness
and atrophy may result in joint hypermobility and
increased traction on the nerves. This type of pain is
suggested in case of suprascapular nerve entrap-
ment [12].
Until now little attention has been given to my-
ofascial and nerve compression pain. As they tend
to be less responsive to opioids, the doses of these
drugs can be high and not infrequently toxic [4].
Recently we described several clinical situations in
which nerve compression pain played an important
role (in press). Once interested in the subject we sud-
denly started to see more and more patients with
these afflictions and wondered how important myo-
fascial and nerve compression pain is when the pain
seems to respond insufficiently to the most basic
pharmacological approaches. To answer this ques-
tion we investigated a population of patients, most
of them with cancer, referred to us for improvement
of pain control. The aim of this study was to find out
how often these kinds of patients present with trig-
ger points. If so, can these trigger points be related
to the pain spontaneously reported by the patients.
We also wanted to objectively measure the pressure
pain thresholds at the trigger points.
Material and methods
Patients
The study protocol was approved by the ethical
committee of the Hospice Board and was performed
in a period of two months. The patients were re-
ferred to the different hospice services for improve-
ment of their pain control. During this period 80
patients were admitted to the bedded unit, 32 of
them for pain control. Of the 62 patients attending
the day therapy at that time, at least 27 had unre-
lieved pain symptoms. Nineteen patients were re-
ferred to the outpatient clinic, all for pain control.
Thus the potential population of patients consisted
of 78 patients. Thirty three patients satisfied all in-
clusion criteria and were asked to participate in the
study. The inclusion criteria were: age > 18 years,
referral for pain control, prognosis longer than 4
weeks, Karnofsky performance score > 50%, able
to communicate in English and capable to give in-
formed consent. Patients treated with steroid injec-
tions for myofascial and/or nerve compression pain
in the past 2 months were excluded. Verbal and
written information about the procedure was given
and all 33 patients gave their written consent. None
of the participating patients finished the study pre-
maturely, although they were aware they could with-
draw at any moment.
Patient’s demographics and diagnoses are pre-
sented in Table 1. Twenty seven patients (82%) suf-
fered from different types of malignancy. The can-
cer was disseminated in 17 of them (63%). All but 8
patients suffered from different co-morbidities. Sev-
en patients suffered from one co-morbidity, 8 pa-
tients from 2, 7 patients from three and 3 patients
had 4 or more co-morbidities. These co-morbidities
consisted of inactive malignancies (5), diabetes mel-
litus (3), respiratory (6), cerebrovascular (5) and gas-
trointestinal disease (7). However, most frequent
were cardiovascular (16) and musculoskeletal dis-
ease like arthritis and spondylosis (14).
Algometry
To measure the pressure pain threshold (PPT) a
mechanical force gauge or algometer, the Force di-
alTM FDK/FDN 20 (Wagner Instruments, Greenwich,
Connecticut, USA), was used. The gauge has a scale
marked from 1 to 10 kg/cm2, in increments of 0.1 kg/
cm [13]. Readings were obtained by applying a grad-
ually increasing force with the algometer. The instru-
ment was new and calibrated by the manufacturer.
Study protocol
The pain history interview was based on a pro-
tocol corroborated by Oldenmenger et al [14]. The
subjects were asked to mark the areas of ongoing
pain on a body chart and estimated their overall
resting pain intensity using a numeric rating scale
Table 1. Patient demographics and characteristics
Subjects
(n = 33)
Age (years; mean ± SD) 73 ± 11
Gender
Female 18 (55%)
Male 15 (45%)
Diagnosis
Multiple sclerosis 2 (6%)
Parkinson's disease 1 (3%)
COPD 2 (6%)
Diabetes mellitus 1 (3%)
Malignancy 27 (82%)
Head-neck region 1
Heamatolo-oncology 3
Breast 3
Lung 6
Urologic 6
Gastrointestional 7
Unknown primary 1
SD — standard deviation; COPD — chronic obstructive pulmonary
disease
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(NRS) where 0 means no pain at all and 10 the
worst pain possible. Then the patients were asked
about pain characteristics and the interference with
daily life activities. The effect of analgesic medica-
tion and their adverse effects were also part of this
interview.
The patients were then subjected to a physical
examination. Thirteen bilateral areas of the body
were investigated for the presence of trigger points.
Nine areas were known to be frequently affected
with myofascial (M), nerve compression (N) or com-
bination (C) trigger points. Four areas were selected
as control areas as they were known not to be relat-
ed to trigger points. This method was derived from
the literature [13, 15–17].
Areas investigated (see Figure 1):
— occiput: bilateral, at the suboccipital muscle in-
sertions (M);
— upper trapezius: bilateral, angle of the neck (M);
— lower cervical: bilateral, at the anterior aspects
of the intertransverse spaces at C5–C7 [M];
— supraspinatus: bilateral, suprascapular notch (C);
— trapezius: bilateral, mid back along scapula (M);
— subcostal nerve Th12: bilateral, ± 9 cm from
anterior superior iliac spine (N);
— lateral cutaneous branch Iliohypogastric nerve:
bilateral, ± 13 cm from anterior superior iliac
spine (N);
— gluteal: bilateral, in upper outer quadrants of
buttocks in anterior fold of muscle (M);
— lateral femoral cutaneous nerve: bilateral, ±1
cm inferior of anterior superior iliac spine (N).
Control areas:
— deltoid: bilateral, middle portion;
— thumbnail: bilateral;
— quadriceps femoris: bilateral, mid anterior;
— big toenail: bilateral.
To avoid patient and investigator related bias
the sequence in which the areas were investigated,
was randomised by a computer program that was
especially designed for this study.
Due to poor mobility of most patients, the phys-
ical examination was done in a sitting position. Min-
imal criteria, local tenderness and/or nodules on pal-
pation, were used to diagnose a trigger point [18–
20]. Following palpation, the pressure pain thresh-
old (PPT) was measured using an algometer. The
shaft of the instrument was placed vertical to the
examined surface. The patient was instructed to say
“yes” when the sensation of pressure changed to
pain. Pressure was increased at approximately 1 kg/
cm2/s. The registered pressure representing PPT was
then recorded.
The interview and the physical examination were
taken in one session and by the same investigator
(WW). To gain experience with the method and with
the protocol a pilot study on 6 consecutive patients
was performed. The results of the pilot are not in-
cluded in this report.
Statistical analysis
The statistical analysis was done using Excel for
Windows and the Statistical Package for the Social
Sciences (SPSS). Descriptive statistics were sum-
Figure 1. The areas investigated for the presence of trigger points
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Table 3.  Overall pain intensity
NRS score Number of patients
0 — no pain 8
1–3 — mild pain 4
4–6 — moderate pain 14
7–10 — severe pain 6
Missing value 1
NRS — numerical rating scale
marised using mean, median values and standard
deviation. Correlation analysis was undertaken with
the Pearson correlation test. The p values £ 0.05
were accepted as significant.
Results
Pain history
The body charts revealed 74 anatomically dis-
tinct locations. They were grouped into nine differ-
ent categories (see Table 2). The most frequent pain
locations were shoulders, lower back, sacrum and
lower limbs. Fourteen patients (42%) presented with
one, 11 (33%) with two, 4 (12%) with three and 4
(12%) with four or more painful areas. Two pa-
tients initially complained of “pain everywhere”, but
managed to localise the most painful areas of the
body. Twelve patients (36%) suffered pain for more
than a year. Three (10%) had pain for 7–12 months.
Eight patients (24%) had been having pain for 1 to
6 months and 10 (30%) for less than a month.
In 16 patients (48%) the pain onset was gradual
while more acute onset was recorded in 14 patients
(42%). Three patients (10%) could not answer the
question. Nineteen patients (58%) experienced con-
tinuous pain, with or without fluctuations. Ten pa-
tients (30%) experienced pain in attacks without
pain in between. In 4 patients (12%) the pain course
could not be determined in such a detail.
The average pain intensity score (NRS-score) was
4 (SD ± 3). The median was 5. Twenty patients
(63%) described their pain as moderate to severe
which corresponded with a NRS ≥ 4 (see Table 3).
Five patients (15%) described their pain as unbear-
able. Nineteen patients (58%) indicated that the
pain was bearable or even better than usual. Move-
ment was aggravating pain in 21 of patients (63%).
Pain medication
Four patients were not taking pain medication
on the day of assessment. Sixteen patients (55%)
were taking combinations of various analgesics.
Paracetamol was used by 17 patients (52%) and
3 patients (9%) were using a combination of co-
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deine (30 mg)/paracetamol (500 mg). Two other
patients (6%) were only using codeine. Two pa-
tients (6%) were taking tramadol. NSAIDs were
prescribed in 4 patients (12%) and antidepressants
(amitriptyline, citalopram) in 6 cases (18%). Four
patients (12%) were taking gabapentin. Strong opi-
oid analgesics were used by 20 patients (61%) (see
Table 4).
Two patients were using ketamine next to opi-
oid analgesics. One patient had just started on a
syringe driver with low dose diamorphine for
breathlessness.
Of the 29 patients (88%) using pain medication,
18 patients (62%) judged it to be sufficient. Eleven
patients (38%) stated that the prescribed analge-
sics were unsatisfactory.
A dry mouth was the adverse effect most fre-
quently reported (37%). Six patients (18%) com-
plained of dizziness and 5 (15%) of unrelieved
constipation. Other adverse effects were head-
ache, confusion, drowsiness, itch, nausea and
stomach-ache.
Table 4. Patient demographics and characteristics
Drug name Number of patients (%)
Controlled release
Fentanyl 12 (60%)
Morphine sulphate 5 (25%)
Oxycodone 1 (5%)
Immediate release
Morphine sulphate 12 (60%)
Oxycodone 2 (10%)
Methadone 1 (5%)
Figure 2. The amount of trigger points
Physical examination
Missing values
In one patient it was not possible to assess all
the pressure points because of reduced mobility.
Another patient did not want to have the area of
the iliac crest examined, because of “painful swell-
ing” which she did not mention during the inter-
view. In seven patients it was impossible to ob-
tain control values of PPT from the toe nails be-
cause of ingrown toenails and loss of sensitivity
due to diabetic neuropathy or peripheral vascular
disease.
Palpation
Trigger points on palpation were found in 31
patients (94%). The histogram of trigger points is
presented in Figure 2. The median number of trig-
ger points per patient was 6.
The trigger point frequency per area is pre-
sented in Table 5. In all patients, palpation of the
control areas did not bring any trigger points to
light.
In 22 patients (67%), trigger points could be
matched with the pain mentioned during the in-
terview according to Table 6. This matching was
carefully distilled out of different specific sources
[18, 21–23]. In 9 subjects (27%), the presence of
trigger points was unrelated to the pain identified
by the patient prior to physical examination (see
Figure 2).
Although 3 patients (9%) claimed not to have
pain on assessment, only one of them did not have
trigger points.
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number of the trigger points and the mean PPT
(see Figure 4; r = –0.63, p = 0.01).
Discussion
The study population was very much compara-
ble to populations studied previously [2, 3].
However, our study was performed on all pa-
tients referred for pain control, including those  with-
out cancer. Interestingly, in the first study done by
Twycross and Fairfield 39% of patients had one or
more pains unrelated to cancer or treatment; the
most common of these was myofascial pain (12%)
[2]. In the second study done by the same group
and with the same method this latter category was
practically absent (2%) [3]. The authors explained
that the consultant involved in the first study took a
Table 6. Pain pattern per trigger point
Trigger point Pain pattern
Occiput Torticollis, headache, shoulder, neck
Upper trapezius Shoulder, headache (temporal region), neck
Low cervical Headache, shoulder, neck
Supraspinatus Shoulder, neck, upper arm
Trapezius Mid back, neck, shoulder
Subcostal nerve th12 Abdomen, hip, leg
Iliohypogastric nerve Abdomen, hip, leg
Gluteal Low back
Lateral femoral cutaneous nerve Groin, hip
Table 5.  Number of trigger points per area
Pressure point No trigger point present Trigger point present
(n%) (n%)
Occiput L 31 (94) 2 (6)
Occiput R 30 (91) 3 (9)
Upper trapezius L 19 (58) 14 (42)
Upper trapezius R* 15 (45) 18 (55)
Low cervical L* 10 (30) 23 (70)
Low cervical R* 12 (36) 21 (64)
Supraspinatus L 20 (61) 13 (39)
Supraspinatus R 19 (58) 14 (42)
Trapezius L* 16 (48) 17 (52)
Trapezuis R 21 (64) 12 (36)
Subcostal nerve th 12 L (n = 32) 23 (72) 9 (28)
Subcostal nerve th12 R 23 (70) 10 (30)
Iliohypogastric nerve L (n = 31) 19 (61) 12 (39)
Iliohypogastric nerve R (n = 32) 22 (69) 10 (31)
Gluteal L (n = 32) 18 (56) 14 (44)
Gluteal R (n = 32) 19 (59) 13 (41)
Lateral femoral cutaneous nerve L 24 (73) 9 (27)
Lateral femoral cutaneous nerve R 24 (73) 9 (27)
* — four most frequent present trigger points
Pressure pain threshold
In 8 patients (24%), PPT measurement of specif-
ic trigger points was less than 1 kg/cm2. Because of
inaccuracy of the algometer at this level, these read-
ings were recorded as 0 kg/cm2.
For each patient the mean PPT of the investi-
gated areas was calculated. It varied from 1.0 to
7.4 kg/cm2 (median 3.2 kg/cm2). For the control
points, the values varied from 1.7 to 8.9 kg/cm2
(median 4.3 kg/cm2). Low PPT values in the control
areas were correlating with low values for the in-
vestigated areas. A strong and significant correla-
tion was found (r = 0.83, p < 0.01) (see Figure 3).
The inter-individual variability of the PPT was high.
There was no correlation between the NRS-scores
and the mean PPT of the investigated areas. A sig-
nificant inverse relation was found between the
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special interest in myofascial pain. This suggests
that the method used in these two studies was not
specific for myofascial pain and could lead to misin-
terpretation. This was the reason why in our study
the pain interview was supplemented by specific
physical examination.
The main finding of this study is that in the
majority of patients referred for improvement of
pain control, both myofascial as nerve compres-
sion trigger points could be found. In two thirds of
the patients the trigger points could be matched
with the painful areas indicated by the patients. We
do not know how specific this matching is. For some
pain syndromes, such a matching can be straight
forward. For example pain in the fronto-lateral part
of the thigh can be matched with the trigger point
suggesting compression of the lateral femoral cuta-
neous nerve (meralgia paraesthetica) [24]. Pain in
the shoulder can frequently be matched with a pos-
itive trigger point above the suprascapular notch
[25]. This suggests that in some cases treatment of
the trigger points can potentially improve overall
pain control. However, a multitude of trigger points
in patients with advanced disease and frequent pains
from bone and visceral tumour invasion, would sup-
port the idea that visceral pains may also be accom-
panied by trigger points [26, 27]. The convergence-
projection mechanism appears to be consistently
present in visceral pain pathways, explaining how
visceral or other deep tissue pain can activate a
trigger point [28]. It is unknown whether treatment
of trigger points resulting from visceral or deep tis-
sue pain will result in overall pain decrease. This
relationship seems to be present in case of localised
and peripheral origins of pain [29].
Another finding of this study is that low PPT
values for the control points are usually accompa-
nied by lower threshold values for the investigated
areas (r = 0.83, p < 0.01), which suggest individual
changes or predisposition to pain sensitivity. Pa-
tients with more intensive pain may suffer from
generalised sensitisation and lowered pain thresh-
olds which in some places may turn into in physical
pain accompanied by trigger points.
There is an inverse relationship between the num-
ber of trigger points found and the mean PPT of the
investigated areas (r = –0.63, p = 0.01). This sug-
gests that in patients with few trigger points a re-
gional or peripheral cause of pain can be present,
as for example entrapment of one or two single
nerves. In these patients local treatment of the trig-
ger points with pharmacological or non-pharmaco-
logical methods could result in full pain control. In
patients with a multitude of trigger points and low
PPT, it is possible that there is a central cause such
as spinal cord sensitisation [30]. It is reported that
patients with chronic pain may have generalised
hyperalgesia [31]. Another cause can be opioid-in-
duced hyperalgesia [32]. Patients who are using
opioids for pain relief, somewhat paradoxically, may
become more sensitive to pain as a direct result of
the opioid therapy [33].
This study has several limitations. The number
of patients is small and several interesting ques-
tions such as the differences in trigger points be-
Figure 3. Relationship between the mean pressure
pain threshold of the control points and the investigat-
ed areas. PPT — pressure pain treshold [kg/cm3]
Figure 4. Relation between the number of trigger
points and the mean pressure pain threshold of the in-
vestigated areas. PPT — pressure pain treshold [kg/cm3]
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tween the left and the right part of the body, as
well as between males and females could not be
answered.
Algometry is described elaborately for myofas-
cial trigger points, but not for nerve compression
trigger points. In fact, the algometer was difficult
to use at the bone edges of the iliac crest. Problems
using the algometer for PPT measurements of nerve
compression trigger points were mentioned before
by Sterling et al [34]. Repeatability and reliability of
the method were not assessed separately so only
general conclusions could be drawn.
One important trigger point described by Maigne
et al., localised on the posterior iliac crest, 7 cm
from the median line, the place where the superior
cluneal nerve crosses the iliac crest, was unfortu-
nately not included in our study [35]. Only later we
realised how important this trigger point is and
how frequently it is encountered in practice. Add-
ing this point to the list tested by us would greatly
increase the strength of our conclusion.
Conclusion
Many patients with unrelieved pain in advanced
disease may present with trigger points. Some of
the trigger points probably originate because of
regional or peripheral problems like muscle over-
load or nerve entrapment. However others, espe-
cially when multiple, may be due to more general
causes such as spinal cord sensitisation and hence
not amenable to regional measures. Pain by itself,
but also opioids, may increase this sensitisation and
result in increased sensitivity to pain and decreased
pressure pain thresholds.
Attention to the trigger points and to their treat-
ment has the potential of further improvement of
pain control, with the pay-off of lower doses of
opioids and fewer adverse effects.
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